Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas

Yasuko Yamamoto, Naoe Goto, Masao Takemura, Wakana Yamasuge, Kuniaki Yabe, Tsuyoshi Takami, Tatsuhiko Miyazaki, Tamotsu Takeuchi, Makoto Shiraki, Masahito Shimizu, Seiji Adachi, Koshiro Saito, Yuhei Shibata, Nobuhiko Nakamura, Takeshi Hara, Ginette Serrero, Kuniaki Saito, Hisashi Tsurumi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background GP88 (progranulin; PGRN) is a secreted 88 kDa glycosylated protein, with important functions, including inflammation and tumorigenesis. We assessed the significance of GP88 expression in survival outcomes of patients with malignant lymphoma (ML). Methods Serum samples from 254 previously untreated ML patients were examined to measure GP88 concentrations using a sandwich human GP88 ELISA kit. Immunohistochemical analyses were performed to examine GP88 tumor tissue expression. Results The median serum GP88 concentration of ML patients was 91.3 ng/ml, and was significantly higher than that of the control group (median, 57.7 ng/ml) (p < 0.0001). Association between GP88 serum concentrations and overall survival (OS) was examined in patients with diffuse large B cell lymphoma (DLBCL) who had been stratified based on their serum GP88 concentrations. Kaplan Meier survival analysis showed that patients with serum GP88 concentrations of ≤ 116 and > 116 ng/ml, had 5-y OS rates of 70% and 50%, respectively (p = 0.02). The immunohistochemical analyses of GP88 tumor expression revealed that DLBCL patients had lymphoma cells that were positive for GP88. Conclusions High serum GP88 concentrations are associated with poor prognosis in patients with DLBCL.

Original languageEnglish
Pages (from-to)139-146
Number of pages8
JournalClinica Chimica Acta
Volume473
DOIs
Publication statusPublished - 01-10-2017

Fingerprint

Tumors
Lymphoma
Serum
Tissue
Proteins
Neoplasms
Carcinogenesis
Enzyme-Linked Immunosorbent Assay
Inflammation
Control Groups
Survival

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Yamamoto, Yasuko ; Goto, Naoe ; Takemura, Masao ; Yamasuge, Wakana ; Yabe, Kuniaki ; Takami, Tsuyoshi ; Miyazaki, Tatsuhiko ; Takeuchi, Tamotsu ; Shiraki, Makoto ; Shimizu, Masahito ; Adachi, Seiji ; Saito, Koshiro ; Shibata, Yuhei ; Nakamura, Nobuhiko ; Hara, Takeshi ; Serrero, Ginette ; Saito, Kuniaki ; Tsurumi, Hisashi. / Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas. In: Clinica Chimica Acta. 2017 ; Vol. 473. pp. 139-146.
@article{c4ef4f53e3c1438e927a1da7dcf51c29,
title = "Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas",
abstract = "Background GP88 (progranulin; PGRN) is a secreted 88 kDa glycosylated protein, with important functions, including inflammation and tumorigenesis. We assessed the significance of GP88 expression in survival outcomes of patients with malignant lymphoma (ML). Methods Serum samples from 254 previously untreated ML patients were examined to measure GP88 concentrations using a sandwich human GP88 ELISA kit. Immunohistochemical analyses were performed to examine GP88 tumor tissue expression. Results The median serum GP88 concentration of ML patients was 91.3 ng/ml, and was significantly higher than that of the control group (median, 57.7 ng/ml) (p < 0.0001). Association between GP88 serum concentrations and overall survival (OS) was examined in patients with diffuse large B cell lymphoma (DLBCL) who had been stratified based on their serum GP88 concentrations. Kaplan Meier survival analysis showed that patients with serum GP88 concentrations of ≤ 116 and > 116 ng/ml, had 5-y OS rates of 70{\%} and 50{\%}, respectively (p = 0.02). The immunohistochemical analyses of GP88 tumor expression revealed that DLBCL patients had lymphoma cells that were positive for GP88. Conclusions High serum GP88 concentrations are associated with poor prognosis in patients with DLBCL.",
author = "Yasuko Yamamoto and Naoe Goto and Masao Takemura and Wakana Yamasuge and Kuniaki Yabe and Tsuyoshi Takami and Tatsuhiko Miyazaki and Tamotsu Takeuchi and Makoto Shiraki and Masahito Shimizu and Seiji Adachi and Koshiro Saito and Yuhei Shibata and Nobuhiko Nakamura and Takeshi Hara and Ginette Serrero and Kuniaki Saito and Hisashi Tsurumi",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.cca.2017.07.024",
language = "English",
volume = "473",
pages = "139--146",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

Yamamoto, Y, Goto, N, Takemura, M, Yamasuge, W, Yabe, K, Takami, T, Miyazaki, T, Takeuchi, T, Shiraki, M, Shimizu, M, Adachi, S, Saito, K, Shibata, Y, Nakamura, N, Hara, T, Serrero, G, Saito, K & Tsurumi, H 2017, 'Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas', Clinica Chimica Acta, vol. 473, pp. 139-146. https://doi.org/10.1016/j.cca.2017.07.024

Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas. / Yamamoto, Yasuko; Goto, Naoe; Takemura, Masao; Yamasuge, Wakana; Yabe, Kuniaki; Takami, Tsuyoshi; Miyazaki, Tatsuhiko; Takeuchi, Tamotsu; Shiraki, Makoto; Shimizu, Masahito; Adachi, Seiji; Saito, Koshiro; Shibata, Yuhei; Nakamura, Nobuhiko; Hara, Takeshi; Serrero, Ginette; Saito, Kuniaki; Tsurumi, Hisashi.

In: Clinica Chimica Acta, Vol. 473, 01.10.2017, p. 139-146.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas

AU - Yamamoto, Yasuko

AU - Goto, Naoe

AU - Takemura, Masao

AU - Yamasuge, Wakana

AU - Yabe, Kuniaki

AU - Takami, Tsuyoshi

AU - Miyazaki, Tatsuhiko

AU - Takeuchi, Tamotsu

AU - Shiraki, Makoto

AU - Shimizu, Masahito

AU - Adachi, Seiji

AU - Saito, Koshiro

AU - Shibata, Yuhei

AU - Nakamura, Nobuhiko

AU - Hara, Takeshi

AU - Serrero, Ginette

AU - Saito, Kuniaki

AU - Tsurumi, Hisashi

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background GP88 (progranulin; PGRN) is a secreted 88 kDa glycosylated protein, with important functions, including inflammation and tumorigenesis. We assessed the significance of GP88 expression in survival outcomes of patients with malignant lymphoma (ML). Methods Serum samples from 254 previously untreated ML patients were examined to measure GP88 concentrations using a sandwich human GP88 ELISA kit. Immunohistochemical analyses were performed to examine GP88 tumor tissue expression. Results The median serum GP88 concentration of ML patients was 91.3 ng/ml, and was significantly higher than that of the control group (median, 57.7 ng/ml) (p < 0.0001). Association between GP88 serum concentrations and overall survival (OS) was examined in patients with diffuse large B cell lymphoma (DLBCL) who had been stratified based on their serum GP88 concentrations. Kaplan Meier survival analysis showed that patients with serum GP88 concentrations of ≤ 116 and > 116 ng/ml, had 5-y OS rates of 70% and 50%, respectively (p = 0.02). The immunohistochemical analyses of GP88 tumor expression revealed that DLBCL patients had lymphoma cells that were positive for GP88. Conclusions High serum GP88 concentrations are associated with poor prognosis in patients with DLBCL.

AB - Background GP88 (progranulin; PGRN) is a secreted 88 kDa glycosylated protein, with important functions, including inflammation and tumorigenesis. We assessed the significance of GP88 expression in survival outcomes of patients with malignant lymphoma (ML). Methods Serum samples from 254 previously untreated ML patients were examined to measure GP88 concentrations using a sandwich human GP88 ELISA kit. Immunohistochemical analyses were performed to examine GP88 tumor tissue expression. Results The median serum GP88 concentration of ML patients was 91.3 ng/ml, and was significantly higher than that of the control group (median, 57.7 ng/ml) (p < 0.0001). Association between GP88 serum concentrations and overall survival (OS) was examined in patients with diffuse large B cell lymphoma (DLBCL) who had been stratified based on their serum GP88 concentrations. Kaplan Meier survival analysis showed that patients with serum GP88 concentrations of ≤ 116 and > 116 ng/ml, had 5-y OS rates of 70% and 50%, respectively (p = 0.02). The immunohistochemical analyses of GP88 tumor expression revealed that DLBCL patients had lymphoma cells that were positive for GP88. Conclusions High serum GP88 concentrations are associated with poor prognosis in patients with DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=85028473375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028473375&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2017.07.024

DO - 10.1016/j.cca.2017.07.024

M3 - Article

C2 - 28823651

AN - SCOPUS:85028473375

VL - 473

SP - 139

EP - 146

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -